Search

Your search keyword '"LEVIN, SEYMOUR R."' showing total 137 results
Start Over Author "LEVIN, SEYMOUR R."
137 results on '"LEVIN, SEYMOUR R."'

1. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025.

Author

ElSayed, Nuha A., McCoy, Rozalina G., Aleppo, Grazia, Bajaj, Mandeep, Balapattabi, Kirthikaa, Beverly, Elizabeth A., Briggs Early, Kathaleen, Bruemmer, Dennis, Cusi, Kenneth, Echouffo-Tcheugui, Justin B., Ekhlaspour, Laya, Fleming, Talya K., Garg, Rajesh, Khunti, Kamlesh, Lal, Rayhan, Levin, Seymour R., Lingvay, Ildiko, Matfin, Glenn, Napoli, Nicola, and Pandya, Naushira

Subjects
MEDICAL personnel, MEDICAL care, MEDICAL education, TYPE 2 diabetes, RESPIRATORY diseases, INTERPROFESSIONAL education, DENTISTS, NUTRITIONISTS
Abstract

The article "Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025" from Diabetes Care presents the American Diabetes Association's clinical practice recommendations for diabetes care, focusing on person-centered collaborative care and involving an interprofessional team. It offers detailed guidance on communication, assessment, and management of diabetes, including lifestyle changes, pharmacotherapy, and preventive care. The document also addresses the importance of comprehensive medical evaluations, screening for autoimmune diseases, managing bone health, and receiving immunizations to prevent infectious diseases like COVID-19, hepatitis B, influenza, and pneumonia. Additionally, it discusses various health issues related to diabetes, such as fragility fractures, cognitive impairment, dental care, and obstructive sleep apnea, emphasizing the need for screening, lifestyle modifications, medication management, and interprofessional care to address these concerns effectively. [Extracted from the article]

Published
2025
Full Text
View/download PDF

2. In vivo time-resolved autofluorescence measurements to test for glycation of human skin.

Author

Blackwell, Jennifer, Katika, Kamal M, Pilon, Laurent, Dipple, Katrina M, Levin, Seymour R, and Nouvong, Aksone

Subjects
diabetes, time-resolved fluorescence, skin, AGEs, oxidative stress, foot ulcer
Abstract

We present an evaluation of time-resolved fluorescence measurements on human skin for screening type 2 diabetes. In vivo human skin is excited with a pulse diode at 375 nm and pulse width of 700 ps. Fluorescence decays are recorded at four different emission wavelengths: 442, 460, 478, and 496 nm. Experiments are performed at various locations, including the palms, arms, legs, and cheeks of a healthy Caucasian subject to test single-subject variability. The fluorescence decays obtained are modeled using a three-exponential decay. The variations in the lifetimes and amplitudes from one location to another are minimal, except on the cheek. We compare the fluorescent decays of 38 diabetic subjects and 37 nondiabetic subjects, with different skin complexions and of ages ranging from 6 to 85 yr. The average lifetimes for nondiabetic subjects were 0.5, 2.6, and 9.2 ns with fractional amplitudes of 0.78, 0.18, and 0.03, respectively. The effects of average hemoglobin A1c (HbA1c) from the previous 4 yr and diabetes duration are evaluated. While no significant differences between the fluorescence lifetimes of nondiabetic and diabetic subjects are observed, two of the fractional amplitudes are statistically different. Additionally, none of the six fluorescence parameters correlated with diabetes duration or HbA1c. One of the lifetimes as well as two of the fractional amplitudes differ between diabetic subjects with foot ulcers and nondiabetic subjects.

Published
2008

14. Nutrient-Independent Incretin1

Author

Levin, Seymour R., primary, Mayer, Ronald D., additional, Martindale, Robert H., additional, Toomey, Mary L., additional, Adachi, Robert I., additional, and Pehlevanian, Mayda Z., additional

Full Text
View/download PDF

25. Efficacy and Safety of Inhaled Insulin (Exubera)Compared With Subcutaneous Insulin Therapy in PatientsWith Type 2 Diabetes.

Author

Hollander, Priscilla A., Blonde, Lawrence, Rowe, Richard, Mehta, Adi E., Milburn, Joseph L., Hershon, Kenneth S., Chiasson, Jean-Louis, and Levin, Seymour R.

Subjects
INSULIN therapy, HYPOGLYCEMIC agents, INJECTIONS, HYPOGLYCEMIA, DRUG administration, TREATMENT of diabetes
Abstract

OBJECTIVE -- Glycemic control using inhaled, dry-powder insulin plus a single injection of long-acting insulin was compared with a conventional regimen in patients with type 2 diabetes, which was previously managed with at least two daily insulin injections. RESEARCH DESIGN AND METHODS -- Patients were randomized to 6 months' treatment with either premeal inhaled insulin plus a bedtime dose of Ultralente (n = 149) or at least two daily injections of subcutaneous insulin (mixed regular/NPH insulin; n = 150). The primary efficacy end point was the change in HbA[sub1c] from baseline to the end of study. RESULTS -- HbA[sub1c] decreased similarly in the inhaled (-0.7%) and subcutaneous (-0.6%) insulin groups (adjusted treatment group difference: -0.07%, 95% CI -0.32 to 0.17). HbA[sub1c] <7.0% was achieved in more patients receiving inhaled (46.9%) than subcutaneous (31.7%) insulin (odds ratio 2.27, 95% CI 1.24-4.14). Overall hypoglycemia (events per subject-month) was slightly lower in the inhaled (1.4 events) than in the subcutaneous (1.6 events) insulin group (risk ratio 0.89, 95% CI 0.82-0.97), with no difference in severe events. Other adverse events, with the exception of increased cough in the inhaled insulin group, were similar. No difference in pulmonary function testing was seen. Further studies are underway to assess tolerability in the longer term. Insulin antibody binding increased more in the inhaled insulin group. Treatment satisfaction was greater in the inhaled insulin group. CONCLUSIONS -- Inhaled insulin appears to be effective, well tolerated, and well accepted in patients with type 2 diabetes and provides glycemic control comparable to a conventional subcutaneous regimen. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

38. Diphenylhydantoin.

Author

Levin, Seymour R., Reed, James W., Ching, King-Nien, Davis, John W., Blum, Robert, and Forsham, Peter H.

Published
1973

41. Carbohydrate Tolerance in Cystic Fibrosis Is Closely Linked to Pancreatic Exocrine Function

Author

GEFFNER, MITCHELL E., LIPPE, BARBARA M., KAPLAN, SOLOMON A., ITAMI, ROBERT M., GILLARD, BAIBA K., LEVIN, SEYMOUR R., and TAYLOR, IAN L.

Abstract

We evaluated carbohydrate tolerance in nine thin cystic fibrosis (CF) patients and in six controls, measuring responsiveness to the following insulinotropic secretagogues: oral glucose, IV glucose, and IV tolbutamide. Glucose responses segregated patients into two groups: Group I with normal carbohydrate tolerance associated with normal to slightly increased insulin responses, and Group II with impaired carbohydrate tolerance associated with insulinopenia. This latter group included one patient with frank diabetes. The CF patients demonstrated a significant positive correlation between insulin secretion, in response to each secretagogue, and pancreatic exocrine function as measured by serum pancreatic amylase isoenzyme concentration. Pancreatic a-cell function, as reflected by basal plasma glucagon concentrations, also correlated well with exocrine function in the CF patients, excluding the diabetic individual. The enteroinsular axis of the CF group was intact as reflected by normal plasma gastric inhibitory polypeptide concentrations in Group I and by elevated levels, basally and in response to oral glucose, in the insulinopenic Group II patients. Furthermore, those patients with impaired tolerance demonstrated a greater magnitude of insulinopenia compared to controls following IV glucose and possibly IV tolbutamide, than following oral glucose.

Published
1984

42. Endocrine Effects of NaloxoneInduced Opiate Receptor Blockade

Author

Morley, John E., Baranetsky, Nicholas G., Wingert, Terence D., Carlson, Harold E., Hershman, Jerome M., Melmed, Shlomo, Levin, Seymour R., Jamison, Kay R., Weitzman, Richard, Chang, H. Jeffrey, and Varner, Albert A.

Published
1980

43. Insulin Resistance in a Young Man With Cystic Fibrosis

Author

Geffner, Mitchell E., Lippe, Barbara M., Itami, Robert M., Kaplan, Solomon A., Gillard, Baiba K., Levin, Seymour R., and Taylor, Ian L.

Abstract

• An 18-year-old man had cystic fibrosis (CF) and insulin-resistant carbohydrate intolerance characterized by (1) obesity, basal hyperinsulinemia, and hyperglucagonemia; (2) impaired oral glucose tolerance; (3) hyperinsulinemia in response to oral and intravenous (IV) administration of glucose and to IV administration of tolbutamide; (4) exaggerated gastric inhibitory polypeptide secretion following orally administered glucose; and (5) diminished sensitivity to insulin administered IV compared with other patients with CF. Both parents also demonstrate basal and stimulated hyperinsulinemia in response to orally administered glucose. The long-term outlook for patients with CF is improving, and more patients are surviving childhood. Thus, it should be recognized that an insulin-resistant form of carbohydrate intolerance may develop in patients with CF with obesity and/or genetic risk factors.(AJDC 1984;138:677-680)

Published
1984
Full Text
View/download PDF

48. Cryohypophysectomy for acromegaly

Author

Levin, Seymour R., primary, Hofeldt, Fred D., additional, Schneider, Victor, additional, Becker, Nathan, additional, Karam, John H., additional, Seymour, Robert J., additional, Adams, John E., additional, and Forsham, Peter H., additional

Published
1974
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results